Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy.

Derya Tilki; Shahrokh F Shariat; Yair Lotan; Michael Rink; Pierre I Karakiewicz; Mark P Schoenberg; Seth P Lerner; Guru Sonpavde; Arthur I Sagalowsky; Amit Gupta

doi:10.1111/j.1464-410X.2012.11455.x

Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy.

Standard

Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. / Tilki, Derya; Shariat, Shahrokh F; Lotan, Yair; Rink, Michael; Karakiewicz, Pierre I; Schoenberg, Mark P; Lerner, Seth P; Sonpavde, Guru; Sagalowsky, Arthur I; Gupta, Amit.

In: BJU INT, Vol. 111, No. 8, 8, 2013, p. 1215-1221.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Tilki, D, Shariat, SF, Lotan, Y, Rink, M, Karakiewicz, PI, Schoenberg, MP, Lerner, SP, Sonpavde, G, Sagalowsky, AI & Gupta, A 2013, 'Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy.', BJU INT, vol. 111, no. 8, 8, pp. 1215-1221. https://doi.org/10.1111/j.1464-410X.2012.11455.x

APA

Tilki, D., Shariat, S. F., Lotan, Y., Rink, M., Karakiewicz, P. I., Schoenberg, M. P., Lerner, S. P., Sonpavde, G., Sagalowsky, A. I., & Gupta, A. (2013). Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU INT, 111(8), 1215-1221. [8]. https://doi.org/10.1111/j.1464-410X.2012.11455.x

Vancouver

Tilki D, Shariat SF, Lotan Y, Rink M, Karakiewicz PI, Schoenberg MP et al. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU INT. 2013;111(8):1215-1221. 8. https://doi.org/10.1111/j.1464-410X.2012.11455.x

Bibtex

@article{0084c341e41b4e219cb8278532eef515,

title = "Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy.",

abstract = "OBJECTIVE: To determine the outcomes of patients with final pathological stage T1N0 disease after radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB) and to determine whether lymphovascular invasion (LVI) is an independent predictor of prognosis in these patients.PATIENTS AND METHODS: Records of 958 consecutive patients who underwent RC at three academic centres were reviewed. A total of 101 patients with negative lymph nodes and with final stage (the higher of the pre-RC clinical/transurethral resection [TUR] and post-RC pathological stages) T1 UCB were identified. The median (range) follow-up was 38 (0.4-177) months and the median (range) number of nodes examined was 19 (9-80).RESULTS: Overall, 12/101 (11.9%) patients experienced cancer recurrence and 7/101 (6.9%) died from their cancer. The 3-year recurrence-free survival probability (SD) was 0.89 (0.04) and 3-year cancer-specific survival probability (SD) was 0.96 (0.02). Six of 101 (6%) patients had LVI, of whom four experienced disease recurrence and three died from bladder cancer. All recurrences and deaths occurred in patients who had either LVI and/or concomitant carcinoma in situ. On multivariable analysis, LVI (hazard ratio [HR] 4.9, P = 0.01) and higher pathological stage (HR 8.5, P = 0.04) predicted cancer recurrence and LVI (HR 6.7, P = 0.01) predicted cancer-specific survival.CONCLUSIONS: LVI helps identify patients with final pathological T1N0 UCB who are at significantly increased risk of bladder cancer recurrence and death. These patients should be considered for close monitoring after cystectomy.",

keywords = "Adult, Aged, Aged, 80 and over, Carcinoma, Transitional Cell, Cystectomy, Female, Follow-Up Studies, Humans, Incidence, Lymph Nodes, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Probability, Prognosis, Retrospective Studies, Survival Rate, United States, Urinary Bladder Neoplasms",

author = "Derya Tilki and Shariat, {Shahrokh F} and Yair Lotan and Michael Rink and Karakiewicz, {Pierre I} and Schoenberg, {Mark P} and Lerner, {Seth P} and Guru Sonpavde and Sagalowsky, {Arthur I} and Amit Gupta",

note = "{\textcopyright} 2012 BJU International.",

year = "2013",

doi = "10.1111/j.1464-410X.2012.11455.x",

language = "English",

volume = "111",

pages = "1215--1221",

journal = "BJU INT",

issn = "1464-4096",

publisher = "Wiley-Blackwell",

number = "8",

}

RIS

TY - JOUR

T1 - Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy.

AU - Tilki, Derya

AU - Shariat, Shahrokh F

AU - Lotan, Yair

AU - Rink, Michael

AU - Karakiewicz, Pierre I

AU - Schoenberg, Mark P

AU - Lerner, Seth P

AU - Sonpavde, Guru

AU - Sagalowsky, Arthur I

AU - Gupta, Amit

PY - 2013

Y1 - 2013

N2 - OBJECTIVE: To determine the outcomes of patients with final pathological stage T1N0 disease after radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB) and to determine whether lymphovascular invasion (LVI) is an independent predictor of prognosis in these patients.PATIENTS AND METHODS: Records of 958 consecutive patients who underwent RC at three academic centres were reviewed. A total of 101 patients with negative lymph nodes and with final stage (the higher of the pre-RC clinical/transurethral resection [TUR] and post-RC pathological stages) T1 UCB were identified. The median (range) follow-up was 38 (0.4-177) months and the median (range) number of nodes examined was 19 (9-80).RESULTS: Overall, 12/101 (11.9%) patients experienced cancer recurrence and 7/101 (6.9%) died from their cancer. The 3-year recurrence-free survival probability (SD) was 0.89 (0.04) and 3-year cancer-specific survival probability (SD) was 0.96 (0.02). Six of 101 (6%) patients had LVI, of whom four experienced disease recurrence and three died from bladder cancer. All recurrences and deaths occurred in patients who had either LVI and/or concomitant carcinoma in situ. On multivariable analysis, LVI (hazard ratio [HR] 4.9, P = 0.01) and higher pathological stage (HR 8.5, P = 0.04) predicted cancer recurrence and LVI (HR 6.7, P = 0.01) predicted cancer-specific survival.CONCLUSIONS: LVI helps identify patients with final pathological T1N0 UCB who are at significantly increased risk of bladder cancer recurrence and death. These patients should be considered for close monitoring after cystectomy.

AB - OBJECTIVE: To determine the outcomes of patients with final pathological stage T1N0 disease after radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB) and to determine whether lymphovascular invasion (LVI) is an independent predictor of prognosis in these patients.PATIENTS AND METHODS: Records of 958 consecutive patients who underwent RC at three academic centres were reviewed. A total of 101 patients with negative lymph nodes and with final stage (the higher of the pre-RC clinical/transurethral resection [TUR] and post-RC pathological stages) T1 UCB were identified. The median (range) follow-up was 38 (0.4-177) months and the median (range) number of nodes examined was 19 (9-80).RESULTS: Overall, 12/101 (11.9%) patients experienced cancer recurrence and 7/101 (6.9%) died from their cancer. The 3-year recurrence-free survival probability (SD) was 0.89 (0.04) and 3-year cancer-specific survival probability (SD) was 0.96 (0.02). Six of 101 (6%) patients had LVI, of whom four experienced disease recurrence and three died from bladder cancer. All recurrences and deaths occurred in patients who had either LVI and/or concomitant carcinoma in situ. On multivariable analysis, LVI (hazard ratio [HR] 4.9, P = 0.01) and higher pathological stage (HR 8.5, P = 0.04) predicted cancer recurrence and LVI (HR 6.7, P = 0.01) predicted cancer-specific survival.CONCLUSIONS: LVI helps identify patients with final pathological T1N0 UCB who are at significantly increased risk of bladder cancer recurrence and death. These patients should be considered for close monitoring after cystectomy.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Transitional Cell

KW - Cystectomy

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Incidence

KW - Lymph Nodes

KW - Lymphatic Metastasis

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Neoplasm Staging

KW - Probability

KW - Prognosis

KW - Retrospective Studies

KW - Survival Rate

KW - United States

KW - Urinary Bladder Neoplasms

U2 - 10.1111/j.1464-410X.2012.11455.x

DO - 10.1111/j.1464-410X.2012.11455.x

M3 - SCORING: Journal article

C2 - 23181623

VL - 111

SP - 1215

EP - 1221

JO - BJU INT

JF - BJU INT

SN - 1464-4096

IS - 8

M1 - 8

ER -